BCM
CLB icon

Blume Capital Management’s Core Laboratories CLB Stock Holding History

Blume Capital Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50
Closed -$6K – 204
2017
Q1 		$6K Hold
50
– – ﹤0.01% 168
2016
Q4 		$6K Buy
+50
New +$5.54K ﹤0.01% 179

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 16.04% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Blume Capital Management's CLB Position: Q2 2017 in Review

Blume Capital Management sold out of Core Laboratories (CLB) in Q2 2017, closing a stake of 50 shares — an estimated $6K sold.

Blume Capital Management first reported a position in CLB in Q4 2016 and held it in 2 quarters. The position peaked at $6K in Q1 2017. 360 funds tracked by Wall St. Rank hold CLB as of Q2 2017.

  • Blume Capital Management reported no remaining Core Laboratories position as of Q2 2017 after selling out during the quarter.
  • Blume Capital Management sold 50 Core Laboratories shares in Q2 2017, an estimated $6K.
  • Blume Capital Management first reported a position in Core Laboratories in Q4 2016 and held it in 2 quarters.
  • Blume Capital Management's Core Laboratories position peaked at $6K in Q1 2017.
  • 360 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2017.

Based on Blume Capital Management's 13F filing for Q2 2017, filed 8 Aug 2017.